G
Gerald R. Donowitz
Researcher at University of Virginia
Publications - 43
Citations - 4499
Gerald R. Donowitz is an academic researcher from University of Virginia. The author has contributed to research in topics: Neutropenia & Pneumonia. The author has an hindex of 21, co-authored 43 publications receiving 4359 citations. Previous affiliations of Gerald R. Donowitz include Indiana University & University of Virginia Health System.
Papers
More filters
Journal ArticleDOI
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
Thomas J. Walsh,Peter G. Pappas,Drew J. Winston,Hillard M. Lazarus,Finn Bo Petersen,John Raffalli,Saul Yanovich,Patrick J. Stiff,Richard N. Greenberg,Gerald R. Donowitz,Mindy G. Schuster,Annette C. Reboli,John R. Wingard,Carola A.S. Arndt,John F. Reinhardt,Susan Hadley,Robert W. Finberg,Michel Laverdière,John R. Perfect,Gary Garber,Giuseppe Fioritoni,Eli Anaissie,Jeanette Y. Lee +22 more
TL;DR: Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever in a randomized, international, multicenter trial.
Journal ArticleDOI
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Thomas J. Walsh,Hedy Teppler,Gerald R. Donowitz,Johan Maertens,Lindsey R. Baden,Anna Dmoszynska,Oliver A. Cornely,Michael R. Bourque,Robert J. Lupinacci,Carole A. Sable,Ben E. dePauw +10 more
TL;DR: Caspofungin is as effective as and generally better tolerated than liposomal amphotericin B when given as empirical antifungal therapy in patients with persistent fever and neutropenia.
Journal ArticleDOI
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial
Thomas J. Walsh,Issam I Raad,Thomas F. Patterson,Pranatharthi H. Chandrasekar,Gerald R. Donowitz,Richard J. Graybill,Reginald Greene,Ray Y Hachem,Susan Hadley,Raoul Herbrecht,Amelia Langston,Arnold Louie,Patricia Ribaud,Brahm H. Segal,David A. Stevens,Jo Anne H. Van Burik,Charles S. White,Gavin Corcoran,Jagadish Gogate,Jagadish Gogate,Gopal Krishna,Lisa D. Pedicone,Catherine Hardalo,John R. Perfect +23 more
TL;DR: Findings demonstrate that posaconazole is an alternative to salvage therapy for patients with invasive aspergillosis who are refractory to or intolerant of previous antifungal therapy.
Journal ArticleDOI
Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting
Luis Ostrosky-Zeichner,Carole A. Sable,Jack D. Sobel,Barbara D. Alexander,Gerald R. Donowitz,V. L. Kan,Carol A. Kauffman,Daniel H. Kett,Robert A. Larsen,Vicki A. Morrison,Marcio Nucci,Peter G. Pappas,M. E. Bradley,S. Major,Louise Zimmer,Dennis Wallace,William E. Dismukes,John H. Rex +17 more
TL;DR: The study presented here was performed in order to create a rule that identifies subjects at high risk for invasive candidiasis in the intensive care setting, and the best performing rule was as follows.
Journal ArticleDOI
Drug therapy. Beta-lactam antibiotics (2).
TL;DR: The pharmacologic characteristics of first- and second-generation cephalosporins have previously been reviewed, and only selected aspects of the most important agents will be mentioned here.